Operaciones VBI Vaccines Inc. - VBIV CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.07 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
VBI Vaccines Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 2.98 |
| Abrir* | 2.88 |
| Cambio de 1 año* | 223.6% |
| Rango del día* | 2.84 - 2.94 |
| Rango de 52 semanas | 2.35-40.50 |
| Volumen medio (10 días) | 73.33K |
| Volumen medio (3 meses) | 2.26M |
| Capitalización de mercado | 24.75M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 8.61M |
| Ingresos | 1.44M |
| EPS | -13.92 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 1.83 |
| Próxima fecha de resultados | Aug 7, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| May 30, 2023 | 2.98 | 0.16 | 5.67% | 2.82 | 3.04 | 2.79 |
| May 26, 2023 | 2.84 | 0.11 | 4.03% | 2.73 | 2.85 | 2.69 |
| May 25, 2023 | 2.72 | -0.22 | -7.48% | 2.94 | 2.99 | 2.50 |
| May 24, 2023 | 2.94 | -0.17 | -5.47% | 3.11 | 3.16 | 2.87 |
| May 23, 2023 | 3.21 | 0.18 | 5.94% | 3.03 | 3.29 | 3.03 |
| May 22, 2023 | 3.09 | 0.06 | 1.98% | 3.03 | 3.22 | 2.94 |
| May 19, 2023 | 3.00 | 0.18 | 6.38% | 2.82 | 3.02 | 2.81 |
| May 18, 2023 | 2.80 | -0.09 | -3.11% | 2.89 | 2.92 | 2.68 |
| May 17, 2023 | 2.90 | -0.03 | -1.02% | 2.93 | 2.96 | 2.83 |
| May 16, 2023 | 2.96 | -0.06 | -1.99% | 3.02 | 3.06 | 2.88 |
| May 15, 2023 | 3.03 | 0.05 | 1.68% | 2.98 | 3.11 | 2.96 |
| May 12, 2023 | 2.94 | -0.12 | -3.92% | 3.06 | 3.10 | 2.77 |
| May 11, 2023 | 3.06 | -0.05 | -1.61% | 3.11 | 3.17 | 3.01 |
| May 10, 2023 | 3.13 | 0.02 | 0.64% | 3.11 | 3.22 | 3.11 |
| May 9, 2023 | 3.19 | 0.35 | 12.32% | 2.84 | 3.26 | 2.79 |
| May 8, 2023 | 2.90 | 0.17 | 6.23% | 2.73 | 2.90 | 2.63 |
| May 5, 2023 | 2.72 | 0.03 | 1.12% | 2.69 | 2.75 | 2.63 |
| May 4, 2023 | 2.66 | -0.22 | -7.64% | 2.88 | 2.95 | 2.62 |
| May 3, 2023 | 2.90 | 0.11 | 3.94% | 2.79 | 2.90 | 2.78 |
| May 2, 2023 | 2.83 | -0.05 | -1.74% | 2.88 | 2.93 | 2.72 |
VBI Vaccines Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Thursday, June 22, 2023 | ||
| Hora (UTC) (UTC) 15:30 | País US
| Evento VBI Vaccines Inc Annual Shareholders Meeting VBI Vaccines Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 23, 2023 | ||
| Hora (UTC) (UTC) 15:00 | País US
| Evento VBI Vaccines Inc Annual Shareholders Meeting VBI Vaccines Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Hora (UTC) (UTC) 12:30 | País US
| Evento Q2 2023 VBI Vaccines Inc Earnings Release Q2 2023 VBI Vaccines Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 8, 2023 | ||
| Hora (UTC) (UTC) 13:00 | País US
| Evento Q3 2023 VBI Vaccines Inc Earnings Release Q3 2023 VBI Vaccines Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 1.082 | 0.631 | 1.061 | 2.221 | 3.355 |
| Ingresos | 1.082 | 0.631 | 1.061 | 2.221 | 3.355 |
| Coste de los ingresos, total | 11.276 | 10.77 | 9.168 | 7.904 | 4.509 |
| Beneficio bruto | -10.194 | -10.139 | -8.107 | -5.683 | -1.154 |
| Gastos totales de explotación | 83.074 | 68.663 | 44.678 | 54.62 | 63.763 |
| Gastos de venta/general/administración Gastos, total | 56.12 | 38.335 | 20.651 | 14.092 | 14.509 |
| Investigación y desarrollo | 15.506 | 19.558 | 14.859 | 26.332 | 38.443 |
| Ingresos de explotación | -81.992 | -68.032 | -43.617 | -52.399 | -60.408 |
| Ingresos por intereses (gastos), netos No operativos | -31.311 | -1.721 | -2.613 | -2.414 | -3.192 |
| Ingresos netos antes de impuestos | -113.303 | -69.753 | -46.23 | -54.813 | -63.6 |
| Ingresos netos después de impuestos | -113.303 | -69.753 | -46.23 | -54.813 | -63.6 |
| Beneficio neto antes de partidas extra. Elementos | -113.303 | -69.753 | -46.23 | -54.813 | -63.6 |
| Ingresos netos | -113.303 | -69.753 | -46.23 | -54.813 | -63.6 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -113.303 | -69.753 | -46.23 | -54.813 | -63.6 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -113.303 | -69.753 | -46.23 | -54.813 | -63.6 |
| Beneficio neto diluido | -113.303 | -69.753 | -46.23 | -54.813 | -63.6 |
| Promedio ponderado de acciones diluidas | 8.60772 | 8.49739 | 7.27491 | 3.98115 | 2.18804 |
| BPA diluido sin partidas extraordinarias | -13.163 | -8.20876 | -6.35472 | -13.7681 | -29.0671 |
| BPA normalizado diluido | -13.143 | -8.20876 | -6.35472 | -12.1877 | -26.1869 |
| Gastos (ingresos) extraordinarios | 0.172 | 0 | 6.292 | 6.302 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 0.485 | 0.293 | 0.317 | 0.346 | 0.126 |
| Ingresos | 0.485 | 0.293 | 0.317 | 0.346 | 0.126 |
| Coste de los ingresos, total | 3.559 | 3.328 | 2.672 | 2.522 | 2.754 |
| Beneficio bruto | -3.074 | -3.035 | -2.355 | -2.176 | -2.628 |
| Gastos totales de explotación | 19.994 | 21.732 | 22.047 | 23.249 | 16.046 |
| Gastos de venta/general/administración Gastos, total | 13.284 | 15.886 | 14.22 | 15.084 | 10.93 |
| Investigación y desarrollo | 3.151 | 2.518 | 4.983 | 5.643 | 2.362 |
| Ingresos de explotación | -19.509 | -21.439 | -21.73 | -22.903 | -15.92 |
| Ingresos por intereses (gastos), netos No operativos | -8.242 | 0.298 | -3.479 | -22.796 | -5.334 |
| Ingresos netos antes de impuestos | -27.751 | -21.141 | -25.209 | -45.699 | -21.254 |
| Ingresos netos después de impuestos | -27.751 | -21.141 | -25.209 | -45.699 | -21.254 |
| Beneficio neto antes de partidas extra. Elementos | -27.751 | -21.141 | -25.209 | -45.699 | -21.254 |
| Ingresos netos | -27.751 | -21.141 | -25.209 | -45.699 | -21.254 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -27.751 | -21.141 | -25.209 | -45.699 | -21.254 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -27.751 | -21.141 | -25.209 | -45.699 | -21.254 |
| Beneficio neto diluido | -27.751 | -21.141 | -25.209 | -45.699 | -21.254 |
| Promedio ponderado de acciones diluidas | 8.60854 | 8.60772 | 8.60772 | 8.60772 | 8.6077 |
| BPA diluido sin partidas extraordinarias | -3.22366 | -2.45605 | -2.92865 | -5.30907 | -2.46919 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -3.22366 | -2.45605 | -2.90867 | -5.30907 | -2.46919 |
| Gastos (ingresos) extraordinarios | 0 | 0.172 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 77.69 | 130.284 | 132.041 | 46.963 | 61.731 |
| Efectivo e inversiones a corto plazo | 62.629 | 121.694 | 119.101 | 44.213 | 59.27 |
| Cash | 62.629 | 121.694 | 93.825 | 44.213 | 59.27 |
| Total deudores, neto | 4.127 | 1.446 | 0.077 | 0.201 | 0.056 |
| Accounts Receivable - Trade, Net | 0.094 | 0.008 | 0.077 | 0.201 | 0.056 |
| Total Inventory | 6.599 | 2.576 | 2.152 | 1.075 | 0.911 |
| Other Current Assets, Total | 2.026 | 2.195 | 9.142 | 0.45 | 0.512 |
| Total Assets | 155.086 | 210.276 | 209.372 | 122.201 | 137.605 |
| Property/Plant/Equipment, Total - Net | 15.569 | 14.381 | 12.275 | 11.654 | 8.525 |
| Property/Plant/Equipment, Total - Gross | 23.55 | 19.34 | 15.885 | 14.414 | 10.936 |
| Accumulated Depreciation, Total | -7.981 | -4.959 | -3.61 | -2.76 | -2.411 |
| Goodwill, Net | 2.127 | 2.261 | 2.261 | 2.208 | 8.265 |
| Intangibles, Net | 58.345 | 62.091 | 62.156 | 60.756 | 58.249 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 1.355 | 1.259 | 0.639 | 0.62 | 0.835 |
| Total Current Liabilities | 36.942 | 32.586 | 17.348 | 29.757 | 23.377 |
| Accounts Payable | 12.973 | 4.28 | 3.734 | 1.127 | 6.055 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 9.15 | 12.172 | 1.437 | 1.712 | 4.165 |
| Total Liabilities | 90.923 | 66.394 | 37.667 | 33.946 | 39.472 |
| Total Long Term Debt | 48.888 | 28.441 | 16.329 | 0 | 12.927 |
| Long Term Debt | 48.888 | 28.441 | 16.329 | 0 | 12.927 |
| Deferred Income Tax | |||||
| Other Liabilities, Total | 5.093 | 5.367 | 3.99 | 4.189 | 3.168 |
| Total Equity | 64.163 | 143.882 | 171.705 | 88.255 | 98.133 |
| Common Stock | 442.312 | 442.235 | 403.528 | 284.965 | 246.417 |
| Additional Paid-In Capital | 90.02 | 81.583 | 75.53 | 66.43 | 63.449 |
| Retained Earnings (Accumulated Deficit) | -489.609 | -378.371 | -308.618 | -262.388 | -207.575 |
| Other Equity, Total | 21.44 | -1.565 | 1.265 | -0.752 | -4.158 |
| Total Liabilities & Shareholders’ Equity | 155.086 | 210.276 | 209.372 | 122.201 | 137.605 |
| Total Common Shares Outstanding | 8.60772 | 8.60748 | 8.23381 | 5.94131 | 3.24447 |
| Prepaid Expenses | 2.309 | 2.373 | 1.569 | 1.024 | 0.982 |
| Accrued Expenses | 14.819 | 16.134 | 12.177 | 12.073 | 12.057 |
| Current Port. of LT Debt/Capital Leases | 0 | 14.845 | 1.1 | ||
| Inversiones a corto plazo | 0 | 25.276 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 51.836 | 77.69 | 96.216 | 92.752 | 112.347 |
| Efectivo e inversiones a corto plazo | 40.392 | 62.629 | 83.55 | 82.414 | 101.337 |
| Cash | 40.392 | 62.629 | 83.55 | 82.414 | 101.337 |
| Inversiones a corto plazo | |||||
| Total deudores, neto | 1.484 | 4.127 | 2.482 | 2.448 | 2.871 |
| Accounts Receivable - Trade, Net | 0.281 | 0.094 | 0.132 | 0.135 | 0.102 |
| Total Inventory | 6.768 | 6.599 | 5.796 | 4.05 | 4.057 |
| Prepaid Expenses | 2.419 | 2.309 | 2.73 | 1.685 | 2.167 |
| Other Current Assets, Total | 0.773 | 2.026 | 1.658 | 2.155 | 1.915 |
| Total Assets | 128.461 | 155.086 | 172.01 | 172.161 | 194.006 |
| Property/Plant/Equipment, Total - Net | 14.682 | 15.569 | 14.614 | 14.397 | 14.692 |
| Goodwill, Net | 2.132 | 2.127 | 2.104 | 2.237 | 2.303 |
| Intangibles, Net | 58.5 | 58.345 | 57.727 | 61.379 | 63.218 |
| Other Long Term Assets, Total | 1.311 | 1.355 | 1.349 | 1.396 | 1.446 |
| Total Current Liabilities | 29.573 | 36.942 | 34.681 | 40.532 | 33.991 |
| Accounts Payable | 9.837 | 12.973 | 11.666 | 5.617 | 3.927 |
| Accrued Expenses | 12.182 | 14.819 | 13.5 | 15.067 | 14.673 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 7.554 | 9.15 | 9.515 | 11.068 | 10.647 |
| Total Liabilities | 83.439 | 90.923 | 88.193 | 66.603 | 64.442 |
| Total Long Term Debt | 49.359 | 48.888 | 48.418 | 21.163 | 24.788 |
| Long Term Debt | 49.359 | 48.888 | 48.418 | 21.163 | 24.788 |
| Other Liabilities, Total | 4.507 | 5.093 | 5.094 | 4.908 | 5.663 |
| Total Equity | 45.022 | 64.163 | 83.817 | 105.558 | 129.564 |
| Common Stock | 442.322 | 442.312 | 442.3 | 442.286 | 442.272 |
| Additional Paid-In Capital | 92.021 | 90.02 | 87.705 | 83.757 | 81.314 |
| Retained Earnings (Accumulated Deficit) | -517.36 | -489.609 | -468.468 | -443.259 | -397.56 |
| Other Equity, Total | 28.039 | 21.44 | 22.28 | 22.774 | 3.538 |
| Total Liabilities & Shareholders’ Equity | 128.461 | 155.086 | 172.01 | 172.161 | 194.006 |
| Total Common Shares Outstanding | 8.60854 | 8.60772 | 8.60772 | 8.60772 | 8.60772 |
| Current Port. of LT Debt/Capital Leases | 8.78 | 4.744 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -113.303 | -69.753 | -46.23 | -54.813 | -63.6 |
| Efectivo de actividades de explotación | -73.695 | -39.908 | -47.05 | -48.712 | -45.533 |
| Efectivo de actividades de explotación | 2.061 | 1.835 | 1.652 | 1.204 | 0.542 |
| Deferred Taxes | 0 | ||||
| Partidas no monetarias | 40.208 | 12.801 | 7.666 | 11.525 | 5.053 |
| Intereses pagados en efectivo | 3.231 | 2.039 | 1.608 | 2.033 | 1.98 |
| Cambios en el capital circulante | -2.661 | 15.209 | -10.138 | -6.628 | 12.472 |
| Efectivo de actividades de inversión | -4.344 | 23.156 | -26 | -3.673 | -5.993 |
| Gastos de capital | -4.344 | -1.995 | -1 | -3.673 | -5.993 |
| Otras partidas de flujo de caja de inversión, total | 0 | 25.151 | -25 | 0 | |
| Efectivo procedente de actividades de financiación | 19.449 | 44.293 | 122.392 | 37.415 | 43.617 |
| Emisión (retiro) de acciones, neto | 0.012 | 33.382 | 124.325 | 40.25 | 46.623 |
| Emisión (amortización) de deuda, neta | 20 | 12 | 4.7 | ||
| Efectos del cambio de divisas | -0.475 | 0.328 | 0.27 | -0.087 | -0.515 |
| Variación neta de la tesorería | -59.065 | 27.869 | 49.612 | -15.057 | -8.424 |
| Elementos de flujo de caja de financiación | -0.563 | -1.089 | -6.633 | -2.835 | -3.006 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -27.751 | -113.303 | -92.162 | -66.953 | -21.254 |
| Cash From Operating Activities | -21.656 | -73.695 | -54.649 | -37.375 | -19.925 |
| Cash From Operating Activities | 0.508 | 2.061 | 1.541 | 1.015 | 0.473 |
| Non-Cash Items | 9.639 | 40.208 | 38.591 | 32.47 | 7.429 |
| Cash Interest Paid | 1.437 | 3.231 | 2.067 | 1.248 | 0.604 |
| Changes in Working Capital | -4.052 | -2.661 | -2.619 | -3.907 | -6.573 |
| Cash From Investing Activities | -0.534 | -4.344 | -2.892 | -1.592 | -0.515 |
| Capital Expenditures | -0.534 | -4.344 | -2.892 | -1.592 | -0.515 |
| Cash From Financing Activities | 0 | 19.449 | 19.449 | 0.012 | 0.012 |
| Financing Cash Flow Items | -0.563 | -0.563 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0 | 0.012 | 0.012 | 0.012 | 0.012 |
| Issuance (Retirement) of Debt, Net | 0 | 20 | 20 | 0 | |
| Foreign Exchange Effects | -0.047 | -0.475 | -0.052 | -0.325 | 0.071 |
| Net Change in Cash | -22.237 | -59.065 | -38.144 | -39.28 | -20.357 |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group530K+
Traders
87K+
Clientes activos mensualmente
$46M+
Volumen mensual de inversión
$31M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
VBI Vaccines Inc. Company profile
Sobre VBI Vaccines Inc
VBI Vaccines Inc. (VBI) es una empresa biofarmacéutica. VBI desarrolla vacunas candidatas que imitan la presentación natural de los virus, diseñadas para provocar el poder innato del sistema inmunitario humano. VBI se centra en atacar y superar enfermedades infecciosas, como la hepatitis B, los coronavirus y el citomegalovirus (CMV), así como cánceres agresivos como el glioblastoma (GBM). Los productos de la empresa incluyen la vacuna contra el virus de la hepatitis B (VHB) de 3 antígenos; VBI-2900, que es un programa de vacuna contra el coronavirus (VBI-2901, VBI-2902, VBI-2905); VBI-1501, que es una vacuna profiláctica contra el CMV; VBI-2601, que es un candidato inmunoterapéutico contra el VHB, y VBI-1901 contra el GBM. La empresa está llevando a cabo el estudio clínico de fase I/IIa del candidato inmunoterapéutico VBI-1901 contra el GBM. También está llevando a cabo el estudio clínico de Fase I del candidato a vacuna profiláctica de COVID-19, VBI-2902 y el estudio clínico con VBI-2905, candidato a vacuna de COVID-19 contra la variante Beta.
El precio actual de la acción VBI Vaccines Inc. en tiempo real es 2.93 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Suntec Reit, Mammoth Energy Services, Taiwan Semiconductor Manufacturing, Rocky Brands, Harrow Health, Inc. y Catalent Inc. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Biotechnology & Medical Research (NEC) |
160 Second Street
Cambridge
CAMBRIDGE
MASSACHUSETTS 02142
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 530.000 traders de todo el mundo que eligen operar con Capital.com